Geographic Atrophy

Latest News

European Union’s Committee for Medicinal Products for Human Use issues negative opinion on Apellis’ pegcetacoplan (Syfovre) injection
European Union’s Committee for Medicinal Products for Human Use issues negative opinion on Apellis’ pegcetacoplan (Syfovre) injection

July 4th 2024

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year
Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year

July 3rd 2024

Geographic atrophy and future plans: What residents should consider
Geographic atrophy and future plans: What residents should consider

July 2nd 2024

4DMT receives IND clearance for 4D-175 for treatment of geographic atrophy
4DMT receives IND clearance for 4D-175 for treatment of geographic atrophy

June 28th 2024

Treatment options for patients with geographic atrophy
Treatment options for patients with geographic atrophy

June 21st 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.